Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Dimesna by Lantern Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval
Dimesna is under clinical development by Lantern Pharma and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Data Insights
Dimesna by Lantern Pharma for Lung Adenocarcinoma: Likelihood of Approval
Dimesna is under clinical development by Lantern Pharma and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase...